DNA RNA and Cells

24 July 2013

NOXXON Pharma Completes Patient Recruitment for Phase IIa Study in Diabetic Nephropathy

24 July 2013

Sarepta Therapeutics Announces Plans to Submit New Drug Application to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy in First Half of 2014

23 July 2013

Arrowhead Begins Phase 1 Trial of RNAi Therapeutic ARC-520 for Treatment of Chronic Hepatitis B Infection

22 July 2013

Cellular Biomedicine Group Completes Enrollment in Phase I Clinical Trial for Knee Osteoarthritis

22 July 2013

Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Significant Reductions of ApoC-III and Triglycerides in Patients With High Triglycerides Taking Fibrates

22 July 2013

OncoSec Medical Presents Positive Immune Response Data from Phase II Study at the 8th World Congress of Melanoma

18 July 2013

Synthetically Optimized HIF-1 Alpha DNA Delivered with Inovio’s Electroporation Technology Provides Significant Therapeutic Effects for Peripheral Arterial Disease in Animal Model

18 July 2013

Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome

16 July 2013

OncoGenex Announces Completion of Patient Enrollment in the Borealis-1(TM) Trial of OGX-427 in Metastatic Bladder Cancer

12 July 2013

RXi Pharmaceuticals Announces Positive Data in Second Phase 1 Multi-Dose Study

11 July 2013

Alnylam Reports Positive Top-Line Results for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis

11 July 2013

Pluristem Completes Enrollment for Phase I/II Muscle Injury Trial

9 July 2013

Calimmune Initiates HIV Stem Cell Study at Two California Research Sites

9 July 2013

Bellicum Pharmaceuticals Initiates Clinical Trial with Novel Controlled Dendritic Cell Immunotherapy in Metastatic Castrate Resistant Prostate Cancer

6 July 2013

MOLOGEN AG: Final results from IMPACT trial with MGN1703 presented at ESMO WCGI 2013

5 July 2013

Cellectis Group Announces Groundbreaking in Vivo Proof of Concept Testing of Their Flagship UCART19 Product for Curative Therapy of Leukemia

3 July 2013

Bioheart Announces Phase III MIRROR Trial for MyoCell Initiated

2 July 2013

Alnylam Presents New Pre-clinical Data on ALN-AT3, an RNAi Therapeutic Targeting Antithrombin (AT) for the Treatment of Hemophilia and Rare Bleeding Disorders

1 July 2013

Idera Pharmaceuticals Announces Results of Phase 1 Clinical Trial of IMO-8400, Toll-like Receptor Antagonist Drug Candidate for Autoimmune and Inflammatory Diseases

1 July 2013

Alnylam Reports Positive Phase II Data for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)

28 June 2013

Dendreon Receives Positive Opinion for PROVENGE in the European Union

28 June 2013

CHMP Gives a Positive Opinion for the Use of VELCADE as Retreatment and for Frontline Induction Therapy before Stem Cell Transplantation

28 June 2013

GlaxoSmithKline’s drisapersen (previously GSK2402968/PRO051) to receive Food and Drug Administration Breakthrough Therapy designation for potential treatment of patients with Duchenne Muscular Dystrophy

26 June 2013

Mesoblast Receives Clearance to Begin Phase 2 Clinical Trial of Mesenchymal Precursor Cells in Diabetic Nephropathy

26 June 2013

Kiadis Pharma Awarded a €3 Million Innovation Credit from the Dutch Government for Phase II Clinical Development Program

24 June 2013

Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Significant Reductions in Triglycerides and APOC-III in Patients with High Triglycerides and Type 2 Diabetes

20 June 2013

Alnylam Scientists Present Pre-clinical Data with ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases

19 June 2013

Sarepta Therapeutics Announces Eteplirsen Demonstrates a Continued Benefit on Walking Test Through 84 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy

18 June 2013

iCo Therapeutics Announces Completion of Trial Enrollment and Clinical Update for iDEAL Phase 2 Study for the Treatment of Diabetic Macular Edema

18 June 2013

OncoSec Medical Announces Completion of Enrollment of Phase II Metastatic Melanoma Trial

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

GPC3-Targeted Immunotherapy Pipeline Review

DLL3-Targeted Immunotherapy Candidates Pipeline Review

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

Aflibercept (Eylea) Biosimilars Pipeline Review

Ranibizumab (Lucentis) Biosimilars Pipeline Review